Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

A Multi-centre, Prospective, Observational Post-Authorization Safety Study to Evaluate the Safety Profile of Budesonide/Glycopyrrolate/Formoterol MDI in Chinese Patients With COPD in Routine Clinical Practice

Sponsors

Lead Sponsor: AstraZeneca

Source AstraZeneca
Brief Summary

This study is an observational, multicenter, prospective, single arm study. The objective of this study is to evaluate the safety of Breztri® Aerosphere® in Chinese patients with COPD in real world clinical practice. The study will enrol approximately 3,050 subjects from about 42 sites around China and followed up for 12 weeks.

Detailed Description

This study is an observational, multicenter, prospective, single arm study. 3,050 subjects who have been prescribed and have planned to take at least one inhalation of BGF MDI will be enrolled into the study.

This is an observational study. BGF MDI treatment will be studied through non-interventional approach. It will be carried out under routine clinical practice and the start or end of BGF MDI and other concomitant treatment will be determined by subjects' treating physicians.

Eligible subjects will be consecutively enrolled in this study at the time they routinely visit their physician and consent to participate in the study. After enrolled successfully, baseline variables will be collected at V1. Subjects will be followed up every 4 weeks after baseline for a total duration of 12 weeks or until study discontinuation, whichever occurs first. V1 and V2 will be followed up by on-site visit and V3 and V4 will be followed up by telephone call visit. For subjects who remain on study drug throughout the study (i.e., complete 4 Visits), a follow up telephone call will be performed at 14 days after the last visit to collect safety information. For subjects who has an Early Discontinuation, 14 days follow up is needed for AE collecting after the discontinuation. For subjects who had been hospitalized during the first 4 weeks of follow-up due to one or more acute exacerbations of COPD, a follow up telephone call will be performed at 28 days after the last visit to collect safety information.

The subjects will be recruited from qualified hospitals. Safety and effectiveness data will be collected following enrollment in the study. Medical records, PROs (COPD Assessment Test [CAT], St. George's Respiratory Questionnaire [SGRQ], Aerosphere Delivery Technology Metered Dose Inhaler Preference Questionnaire [AMPQ], Patient Global Impression of Change [PGIC]) will be the data source in this study.

Primary endpoint will be the incidence of AEs and SAEs in purpose of monitoring the safety profile of BGF MDI.

Overall Status Not yet recruiting
Start Date December 31, 2020
Completion Date December 30, 2022
Primary Completion Date December 30, 2022
Study Type Observational
Primary Outcome
Measure Time Frame
Incidence of all AEs /SAEs 2022-12-30
Secondary Outcome
Measure Time Frame
Change from baseline in CAT score 2022-12-30
Change from baseline in SGRQ score 2022-12-30
ADT MDI preference questionnaire (AMPQ) 2022-12-30
Patient global impression of change (PGIC) 2022-12-30
Mean total COPD cost including the direct and indirect COPD cost 2022-12-30
Enrollment 3050
Condition
Eligibility

Sampling Method: Probability Sample

Criteria:

Inclusion Criteria:

- Give their signed written informed consent to participate

- Age: 18 and above

- Chinese, Female or male

- Patient with diagnosis of COPD as defined by clinicians

- Subjects who have been prescribed and have planned to take at least one inhalation of Budesonide/Glycopyrrolate/Formoterol MDI based on physician's decision

Exclusion Criteria:

Subjects who meet any of the following criteria will not be able to enter the study:

- Subjects who are currently involved in any other interventional studies.

- Drug Allergy: Subjects who have a history of hypersensitivity to formoterol or any other β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI.

- Subjects who received investigational drug treatment within 30 days prior to Visit 1.

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Yongchang Sun Principal Investigator Peking Universicy Third Hospital
Overall Contact

Last Name: AstraZeneca Clinical Study Information Center

Phone: 1-877-240-9479

Email: [email protected]

Location
Facility: Contact: Peking Universicy Third Hospital Yongchang Sun [email protected]
Location Countries

China

Verification Date

October 2020

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Acronym TORES
Patient Data Yes
Study Design Info

Observational Model: Other

Time Perspective: Prospective

Source: ClinicalTrials.gov